EMA Authorised: Kesimpta (ofatumumab) — Novartis Europharm Limited

View source ↗

Summary

Kesimpta (ofatumumab) has been authorised in the EU for Relapsing-Remitting Multiple Sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Status: Authorised. Therapeutic area: Multiple Sclerosis, Relapsing-Remitting. MAH: Novartis Europharm Limited. Decision date: 19/06/2026